131 related articles for article (PubMed ID: 12639966)
41. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
Winkles JA; Alberts GF
Oncogene; 2005 Jan; 24(2):260-6. PubMed ID: 15640841
[TBL] [Abstract][Full Text] [Related]
42. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
43. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
44. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores.
Ahonen LJ; Kallio MJ; Daum JR; Bolton M; Manke IA; Yaffe MB; Stukenberg PT; Gorbsky GJ
Curr Biol; 2005 Jun; 15(12):1078-89. PubMed ID: 15964272
[TBL] [Abstract][Full Text] [Related]
45. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.
Lane HA; Nigg EA
J Cell Biol; 1996 Dec; 135(6 Pt 2):1701-13. PubMed ID: 8991084
[TBL] [Abstract][Full Text] [Related]
46. Identification of a nuclear localization signal in the polo box domain of Plk1.
Lee MS; Huang YH; Huang SP; Lin RI; Wu SF; Li C
Biochim Biophys Acta; 2009 Oct; 1793(10):1571-8. PubMed ID: 19631697
[TBL] [Abstract][Full Text] [Related]
47. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
48. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
49. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade.
Hu MC; Qiu WR; Wang X; Meyer CF; Tan TH
Genes Dev; 1996 Sep; 10(18):2251-64. PubMed ID: 8824585
[TBL] [Abstract][Full Text] [Related]
50. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
52. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression.
Mundt KE; Golsteyn RM; Lane HA; Nigg EA
Biochem Biophys Res Commun; 1997 Oct; 239(2):377-85. PubMed ID: 9344838
[TBL] [Abstract][Full Text] [Related]
53. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
54. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.
Ando K; Ozaki T; Yamamoto H; Furuya K; Hosoda M; Hayashi S; Fukuzawa M; Nakagawara A
J Biol Chem; 2004 Jun; 279(24):25549-61. PubMed ID: 15024021
[TBL] [Abstract][Full Text] [Related]
55. Cell cycle-regulated phosphorylation of the Xenopus polo-like kinase Plx1.
Kelm O; Wind M; Lehmann WD; Nigg EA
J Biol Chem; 2002 Jul; 277(28):25247-56. PubMed ID: 11994303
[TBL] [Abstract][Full Text] [Related]
56. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
[TBL] [Abstract][Full Text] [Related]
57. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
[TBL] [Abstract][Full Text] [Related]
58. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
59. Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase.
Yuan JH; Feng Y; Fisher RH; Maloid S; Longo DL; Ferris DK
Mol Cancer Res; 2004 Jul; 2(7):417-26. PubMed ID: 15280449
[TBL] [Abstract][Full Text] [Related]
60. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
